Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAsset Writedowns and ImpairmentBeginning Cash BalanceCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based CompensationShort-Term Debt issuances
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Sanara MedTech (SMTI) Depreciation & Amortization (CF) (2016 - 2025)

Sanara MedTech (SMTI) has disclosed Depreciation & Amortization (CF) for 15 consecutive years, with $1.0 million as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Depreciation & Amortization (CF) fell 5.88% year-over-year to $1.0 million, compared with a TTM value of $4.9 million through Sep 2025, up 10.8%, and an annual FY2024 reading of $4.9 million, up 33.96% over the prior year.
  • Depreciation & Amortization (CF) was $1.0 million for Q3 2025 at Sanara MedTech, down from $1.1 million in the prior quarter.
  • Across five years, Depreciation & Amortization (CF) topped out at $1.6 million in Q4 2024 and bottomed at $90591.0 in Q1 2021.
  • Average Depreciation & Amortization (CF) over 5 years is $781255.9, with a median of $814881.0 recorded in 2022.
  • The sharpest move saw Depreciation & Amortization (CF) skyrocketed 434.81% in 2022, then decreased 5.88% in 2025.
  • Year by year, Depreciation & Amortization (CF) stood at $201007.0 in 2021, then skyrocketed by 305.12% to $814316.0 in 2022, then skyrocketed by 34.44% to $1.1 million in 2023, then skyrocketed by 46.92% to $1.6 million in 2024, then tumbled by 35.41% to $1.0 million in 2025.
  • Business Quant data shows Depreciation & Amortization (CF) for SMTI at $1.0 million in Q3 2025, $1.1 million in Q2 2025, and $1.1 million in Q1 2025.